|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 31/155 | (2006.01) |
| A61K 38/26 | (2006.01) | ||
| A61K 38/28 | (2006.01) | ||
| A61K 45/06 | (2006.01) |
| (11) | Number of the document | 2329848 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09175877.1 |
| Date of filing the European patent application | 2009-11-13 | |
| (97) | Date of publication of the European application | 2011-06-08 |
| (45) | Date of publication and mention of the grant of the patent | 2012-10-24 |
| (46) | Date of publication of the claims translation | 2013-02-25 |
| (72) |
Silvestre, Louise, FR
Souhami, Elisabeth, FR
Wei, Xiaodan, US
|
| (73) |
Sanofi-Aventis Deutschland GmbH,
Brüningstra e 50, 65929 Frankfurt am Main,
DE
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Liksisenatidas, kaip papildoma terapija su insulinu glarginu ir metforminu, skirtas 2 tipo diabeto gydymui |
| Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes |
| Payment date | Validity (years) | Amount | |
| 2018-10-17 | 10 | 231.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2019-11-13 |